Effect of losartan, an angiotensin II receptor antagonist, on portal pressure in cirrhosis

Hepatology

Volumn 29, Issue 2, 1999, Pages 334-339

  Schneider, Arved Winfried ^a,b   Kalk, Johann Friedrich ^a   Klein, Christian Peter ^a  

^a Heinz Kalk Hospital   (Germany)

^b AGAPLESION MARKUS KRANKENHAUS   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; ISOSORBIDE 5 NITRATE; LOSARTAN; NADOLOL; PROPRANOLOL;

ADULT; ANGIOTENSIN BLOOD LEVEL; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; ESOPHAGUS VARICES; FEMALE; HEMODYNAMIC MONITORING; HUMAN; LIVER CIRRHOSIS; MALE; ORAL DRUG ADMINISTRATION; PATHOGENESIS; PORTAL VEIN BLOOD PRESSURE; PRIORITY JOURNAL;

ADULT; AGED; ANTIHYPERTENSIVE AGENTS; BILIRUBIN; FEMALE; HEMODYNAMIC PROCESSES; HUMANS; HYPERTENSION, PORTAL; KIDNEY; LIVER; LIVER CIRRHOSIS; LOSARTAN; MALE; MIDDLE AGED; RECEPTORS, ANGIOTENSIN; WEIGHT GAIN;

EID: 0032988091     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.510290203     Document Type: Article

References (10)

1. Reichen J. Liver function and pharmacological considerations in pathogenesis and treatment of portal hypertension. HEPATOLOGY 1990;11:1066-1078.
2. Poynard T, Cales P, Pasta L, Ideo G, Pascal J-P, Pagliaro L, Lebrec D, Franco-Italian Multicentric Study Group. Beta-adrenergic-antagonist drugs in the prevention of gastrointestinal bleeding in patients with cirrhosis and esophageal varices. An analysis of data and prognostic factors from 589 patients from four randomized clinical trials. N Engl J Med 1991;324:1532-1538.
3. Lebrec D, Poynard T, Bernuau J, Bercoff E, Novel O, Capron JP, Poupon R, et al. A randomized controlled study of propranolol for prevention of recurrent gastrointestinal bleeding in patients with cirrhosis: a final report. HEPATOLOGY 1984;4:355-358.
4. Bosch J, Mastai R, Kravetz D, Bruix J, Gaya J, Rigua J, Rodés J. Effects of propranolol on azygos venous blood flow and hepatic and systemic hemodynamics in cirrhosis. HEPATOLOGY 1984;4:1200-1205.
5. Garcia-Tsao G, Grace ND, Groszmann RJ, Conn HO, Bermann MM, Patrick MJC, Morse SS, et al. Short-term effects of propranolol on portal venous pressure. HEPATOLOGY 1986;6:101-106.
6. Morillas RM, Planas R, Cabré E, Galán A, Quer JC, Feu F, Garcia Pagan JC, et al. Propranolol plus isosorbide-5-mononitrate for portal hypertension in cirrhosis: long-term hemodynamic and renal effects. HEPATOLOGY 1994;20:1502-1508.
7. Navasa M, Chesta J, Bosch J, Rodés J. Reduction of portal pressure by isosorbide-5-mononitrate in patients with cirrhosis. Gastroenterology 1989;96:1110-1118.
8. Vorobioff J, Picabea E, Gamen M, Villavicencio R, Bordato J, Bessone F, Tanno H, et al. Propranolol compared with propranolol plus isosorbide dinitrate in portal-hypertensive patients: long-term hemodynamic and renal effects. HEPATOLOGY 1993;18:477-484.
9. D'Amico G, Pagliaro L, Bosch J. The treatment of portal hypertension: a meta-analytic review. HEPATOLOGY 1995;1:332-354.
10. Villanueva C, Balanzó J, Novella MT, Soriano G, Sáinz S, Torras X, Cusso X, et al. Nadolol plus isosorbide mononitrate compared with sclerotherapy for the prevention of variceal rebleeding. N Engl J Med 1996;334:1624-1629.